Search Results

The updated vaccine is authorised for individuals aged six months and older and aligns the EU COVID-19 vaccination programme with the currently circulating XFG variant. The European Commission has authorised the Pfizer-BioNTech XFG-adapted COVID-19 vaccine for active immunisation against COVID-19 in individuals aged six months and older across the European Union, Iceland, Liechtenstein and Norway, following a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The approval updates the vaccine composition for the 2026–2027 respiratory season, supporting continued protection against the currently circulating XFG variant while maintaining the established mRNA vaccine platform. Field Content Alert Type Drug Approval Drug Name Pfizer-BioNTech XFG-adapted COVID-19 vaccine (COMIRNATY®, COVID-19 Vaccine, mRNA) Indication Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals aged six months and older. (Pfizer) Therapy Area(s) Infectious Diseases; Vaccines Geography European Union (European Commission) What Happened On 29 July 2026, the European Commission granted marketing authorisation for the Pfizer-BioNTech XFG-adapted COVID-19 vaccine for the 2026–2027 vaccination season. The updated formulation targets the XFG variant of the JN.1 lineage following the EMA Emergency Task Force recommendation and is authorised for active immunisation in individuals aged six months and older throughout all EU Member States, as well as Iceland, Liechtenstein and Norway. This updates the existing marketing authorisation with a revised seasonal vaccine formulation rather than representing a first approval. (Pfizer) Why It Matters The authorisation ensures healthcare providers have an updated COVID-19 vaccine aligned with the variants expected to circulate during the 2026–2027 respiratory season. Updating vaccine composition in response to viral evolution is intended to maintain vaccine relevance, although uptake and public health impact will depend on national vaccination programmes and recommendations. (Pfizer) Supporting Context The approval follows the CHMP's positive opinion issued on 23 July 2026 and the EMA Emergency Task Force recommendation to target the XFG variant after reviewing available epidemiological and immunogenicity data. Pfizer and BioNTech stated that manufacturing had already begun to support vaccine availability ahead of the respiratory virus season. (Pfizer) Key Takeaway The European Commission has authorised an updated Pfizer-BioNTech COVID-19 vaccine targeting the XFG variant, enabling deployment of the 2026–2027 seasonal formulation across the EU. (Pfizer) What to Watch National vaccination recommendations, country-level procurement and rollout schedules, and regulatory decisions in other jurisdictions will determine when the updated vaccine becomes available to eligible populations. (Pfizer) Primary Source https://www.pfizer.com/news/press-release/press-release-detail/european-commission-authorizes-pfizer-and-biontech-xfg Relevant Date 29 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The test gives average-risk adults aged 45 years and older an additional screening option, but positive results still require colonoscopy and the assay is not intended for high-risk surveillance. The US Food and Drug Administration has approved Freenome’s SimpleScreen CRC, a blood-based in vitro diagnostic test for colorectal cancer screening in average-risk adults aged 45 years and older, making it the second FDA-approved blood test for this purpose. The approval may help clinicians engage patients who have not completed established screening, although the test has limited detection of advanced precancerous lesions and does not replace diagnostic or surveillance colonoscopy. Field Content Alert Type Drug Approval Drug Name SimpleScreen CRC Indication Colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease; patients with a positive result should undergo follow-up colonoscopy. Therapy Area(s) Oncology; Gastroenterology; Cancer screening Geography United States (FDA) What Happened On 24 July 2026, the FDA granted premarket approval to SimpleScreen CRC, a qualitative in vitro diagnostic test developed by Freenome that detects molecular signals associated with colorectal cancer using circulating cell-free DNA from plasma. The approval adds a second blood-based colorectal cancer screening test for average-risk adults aged 45 years and older; it is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. Abbott plans to commercialise the test in the United States from autumn 2026. (FDA Access Data) Why It Matters SimpleScreen CRC provides another screening route for eligible adults who may decline or fail to complete colonoscopy or stool-based testing. This could support wider screening participation, but clinicians must explain that an abnormal result requires colonoscopy and that blood-based testing is less effective at identifying precancerous lesions than established screening approaches. (investors.freenome.com) Supporting Context In the PREEMPT CRC study of more than 48,000 asymptomatic, average-risk adults, SimpleScreen CRC demonstrated 81.1% sensitivity for colorectal cancer, 13.7% sensitivity for advanced precancerous lesions and 90.4% specificity for advanced colorectal neoplasia. These results mean the test detected approximately eight in ten cancers but identified a much smaller proportion of advanced precancerous lesions. (investors.freenome.com) Key Takeaway SimpleScreen CRC expands blood-based screening choice for average-risk adults, but it should complement rather than replace higher-performing screening and appropriate colonoscopy follow-up. What to Watch Commercial availability from autumn 2026, incorporation into clinical screening pathways and whether increased convenience translates into higher completion rates among people overdue for colorectal cancer screening. Primary Source https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P250029 Relevant Date 24 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The expanded indication moves radioligand therapy into an earlier stage of metastatic prostate cancer, providing an additional treatment option for eligible patients before progression to castration-resistant disease. The US Food and Drug Administration (FDA) has approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, previously referred to as metastatic hormone-sensitive prostate cancer. The approval expands Pluvicto's use into an earlier treatment setting, offering eligible patients a radioligand therapy alongside standard systemic treatment before progression to metastatic castration-resistant disease. Field Content Alert Type Drug Approval Drug Name Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) Indication In combination with an androgen receptor pathway inhibitor for adults with PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. Patients should be selected using Locametz® (gallium Ga 68 gozetotide) or another FDA-approved PSMA PET imaging agent. (U.S. Food and Drug Administration) Therapy Area(s) Oncology; Prostate Cancer Geography United States (FDA) What Happened On 31 July 2026, the FDA approved Pluvicto in combination with an ARPI for adults with PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. The decision expands Pluvicto's existing indication beyond metastatic castration-resistant prostate cancer into an earlier metastatic treatment setting and is based on results from the Phase III PSMAddition trial. (U.S. Food and Drug Administration) Why It Matters The approval enables eligible patients to receive targeted radioligand therapy earlier in the course of metastatic disease while continuing standard androgen receptor pathway inhibition. It broadens treatment options for PSMA-positive disease, although appropriate patient selection remains dependent on PSMA PET imaging and long-term overall survival data are still maturing. (U.S. Food and Drug Administration) Supporting Context In the PSMAddition trial, Pluvicto plus standard of care reduced the risk of radiographic progression or death compared with ARPI-based standard therapy alone. Overall survival data were immature at the time of approval, although an encouraging trend was reported. (U.S. Food and Drug Administration) Key Takeaway FDA approval extends Pluvicto into the metastatic hormone-sensitive setting, introducing radioligand therapy earlier in the treatment pathway for eligible patients with PSMA-positive disease. (U.S. Food and Drug Administration) What to Watch Longer-term overall survival results from PSMAddition and how rapidly PSMA PET-guided patient selection is incorporated into routine first-line metastatic prostate cancer care. (U.S. Food and Drug Administration) Primary Source https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy Relevant Date 31 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Role of Starting Knowledge in Shaping Competency Growth Medical education builds on what learners already know, and starting knowledge can shape how much they gain. Nuaxia analysed pre- and post-test scores across Moore’s Levels 3a, 3b, and 4 to see how baseline competence drives learning growth. The pattern is clear: learners with lower starting knowledge, especially at Level 3a, make the biggest gains, while those starting higher improve less. Even across different levels, the trend holds. Which means that baseline knowledge is a strong guide to where educational effort will have the most impact. By visualising this relationship, Nuaxia shows how understanding learners’ starting points lets educators target interventions to maximise growth and meaningful knowledge gains across all Moore’s Levels. Key Findings at a Glance Lower baseline → greater growth: Learners in Moore’s Level 3a, with the lowest pre-test scores, showed the largest increases in post-test performance. Moderate baseline → steady gains: Level 3b learners started higher and still made substantial improvements, though smaller than 3a. Higher baseline → smaller gains: Level 4 learners, starting with the highest pre-test scores, had the least room to improve. Baseline predicts nearly 50% of variation: Regression analysis shows R² values around 0.47–0.56 across levels, meaning pre-test scores explain almost half of the differences in learning gains. Ceiling effect is evident: The higher the initial knowledge, the smaller the potential improvement, highlighting the importance of personalised learning approaches. Implication for educators: Tailoring interventions to learners’ starting points maximises growth where it is most needed and supports meaningful learning across all Moore’s Levels. Why These Results Matter These results show that baseline knowledge is a powerful predictor of learning gains across Moore’s Levels. By understanding where learners start, educators can design targeted interventions that maximise growth. In doing so, it ensures resources are focused where they will have the greatest impact and help all learners achieve meaningful knowledge and competency improvements. Methodology The analysis was based on: Pre and Post Assessment total activity score (Moore’s Level 3a, 3b and 4) X axis = Pre-Test (%), Y axis = Absolute % Increase Regression Analysis Learners’ pre- and post-assessment scores (Moore’s Levels 3a, 3b, and 4) were analysed, with the X-axis representing pre-test scores (%) and the Y-axis showing absolute percentage increase. Regression analysis quantified how baseline knowledge predicts learning gains, highlighting the relationship between starting competence and improvement. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. By using baseline knowledge to guide interventions, educators can personalise learning experiences, maximise impact, and ensure that learners at all Moore’s Levels achieve meaningful gains. Nuaxia’s analytics capabilities make it easier to measure, understand, and optimise educational outcomes for future programmes. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Quantifying How Baseline Knowledge Influences Learning Gains in Medical Education Medical education builds on what learners already know, and initial knowledge can dramatically shape how much they gain. By analysing both pre- and post-test scores across multiple interventions, Nuaxia quantified how baseline competence predicts learning growth. The data reveal a clear pattern: the lower the starting knowledge, the greater the improvement, while higher baseline scores leave less room for growth. Through regression analysis and scatter plot visualisation, we show that nearly 50% of the variation in learning gains is explained by pre-test performance. These insights highlight the value of targeting educational strategies to learners’ starting points, ensuring interventions maximise growth where it’s most needed and support all learners in achieving meaningful knowledge gains. Key Findings at a Glance Lower baseline → greater growth: Learners with lower pre-test scores showed the largest increases in post-test performance. Higher baseline → smaller gains: Learners starting with higher pre-test scores had less room to improve. Baseline predicts nearly 50% of variation: Regression analysis shows R² = 0.476, meaning pre-test scores explain almost half of the differences in learning gains. Ceiling effect is evident: The higher the initial knowledge, the smaller the potential improvement — highlighting the importance of personalised learning approaches. Implication for educators: Tailoring interventions to learners’ starting points maximises growth where it’s most needed. Why These Results Matter Baseline knowledge strongly shapes learning outcomes: those starting lower show the greatest gains, while higher-performing learners have less room to improve. These results highlight the value of tailoring education to starting competence, ensuring all learners reach their full potential. By quantifying this relationship, Nuaxia provides actionable insights for optimising medical education. Methodology The analysis was based on: Pre and Post Assessment total activity score (Moore’s Level 3a, 3b and 4) X axis = Pre-Test (%), Y axis = Absolute % Increase Regression Analysis Learners’ pre- and post-assessment scores (Moore’s Levels 3a, 3b, and 4) were analysed, with the X-axis representing pre-test scores (%) and the Y-axis showing absolute percentage increase. Regression analysis quantified how baseline knowledge predicts learning gains, highlighting the relationship between starting competence and improvement. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. For organisations planning a new CME programme or aiming to measure the impact of existing initiatives, Nuaxia’s database and analytics capabilities can help deliver meaningful outcomes. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Assessing cardiology training programmes and their role in improving professional competency. Cardiology remains one of the most data-intensive and guideline-driven therapy areas, making high-quality education essential. To assess the effectiveness of cardiology education, nuaxia analysed behavioural data from cardiology-focused learning activities. This analysis evaluates changes in healthcare professionals' knowledge and competence before and after educational interventions, providing clear evidence of how cardiology education supports learning and clinical confidence. Key Findings at a Glance 90% of Participants Improved Their Scores 90% of HCPs showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 47% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 47% improved 45% remained stable Only 8% saw a decrease This shift underlines how well-structured education meets HCPs where they are and helps them grow, regardless of the starting point. 30% Achieved the Top Score After Medical Education Activity Importantly, 30% of participants progressed to the top performance group, demonstrating that CME activities are driving measurable improvements in HCP knowledge and competence. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (50.0%) or Average (27.5%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (50.0%) or Top (30.0%) categories. This demonstrates that medical education’s power lies not just in teaching, but in transforming practice. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change This benefits not only HCPs but ultimately improves patient outcomes on a global scale. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Examining the impact of dermatology education on knowledge application and patient care quality. Dermatology education must address a broad spectrum of conditions, from chronic inflammatory diseases to complex diagnostic challenges. nuaxia analysed behavioural data from dermatology-focused medical education activities to evaluate how effectively these programmes support healthcare professional learning. By assessing changes in knowledge and competence following educational interventions, this analysis offers objective insights into the value of dermatology education and its role in improving clinical understanding. Key Findings at a Glance 97% of Participants Improved Their Scores Nearly all HCPs showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 79% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 79% improved 19% remained stable Only 2% saw a decrease This highlights how education programmes can support HCPs’ growth, regardless of their initial level of knowledge or experience. 44% Achieved the Top Score After Medical Education Activity 44% of participants reached the top performance group, showing that CME activities are effectively supporting HCPs in achieving high performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (51.6%) or High (33.9%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the Top (43.5%) or High (40.4%) categories. The results underscore that medical education’s true value lies in its ability to change behaviour and outcomes, not just impart information. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change This advancement for HCPs directly contributes to better healthcare outcomes on a global scale. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Evaluating the effectiveness of endocrinology learning interventions to support better clinical practice. Endocrinology requires ongoing education to keep pace with evolving treatment guidelines and long-term disease management strategies. But how effective is endocrinology-focused education in driving meaningful learning outcomes? nuaxia analysed behavioural data from endocrinology education activities to answer this question. Through detailed pre- and post-education analysis, nuaxia assessed changes in knowledge and competence, providing data-backed insights into the real-world impact of endocrinology education programmes. Key Findings at a Glance 87% of Participants Improved Their Scores Nearly nine out of ten participants showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 63% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 63% improved 25% remained stable Only 12% saw a decrease These insights show that personalised, structured education enables HCPs to progress meaningfully from any starting point. 32% Achieved the Top Score After Medical Education Activity Nearly a third of participants reached the top performance group, highlighting the effectiveness of CME activities in supporting HCP learning. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (42.7%) or High (42.7%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (46.5%) or Top (32.0%) categories. This shows that impactful medical education doesn’t just inform - it transforms. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change The benefits reach far beyond learners, fostering measurable improvements in global patient care. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Key findings from neurology education activities and their influence on learning outcomes. Neurology presents unique educational challenges, with intricate disease pathways and rapidly expanding treatment options. To understand how education supports learning in this area, nuaxia analysed behavioural data from neurology-focused medical education activities. This analysis examines changes in knowledge and competence among healthcare professionals, using objective data to uncover how neurology education influences learning outcomes and supports more confident clinical practice. Key Findings at a Glance 97% of Participants Improved Their Scores Nearly all HCPs showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 71% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 71% improved 28% remained stable Only 1% saw a decrease This reflects how thoughtfully designed CME can meet HCPs where they begin and help them achieve their full potential. 48% Achieved the Top Score After Medical Education Activity Almost half of the participants reached the top performance group, showing that CME activities are effectively supporting HCPs in achieving high performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (50.9%) or Average (38.8%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the Top (48.2%) or High (44.2%) categories. This proves that impactful CME equips HCPs to move from knowledge to action. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change By supporting HCP development, these educational programmes drive positive change in patient outcomes across the globe. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Analysing how targeted haematology training enhances understanding and informs treatment decisions. Haematology education plays a vital role in supporting healthcare professionals managing complex and often life-threatening conditions. But how effective are current educational approaches in this field? nuaxia analysed behavioural data from haematology-focused education activities to evaluate their impact on learner knowledge and competence. Using data-driven methodologies, this analysis tracks changes in learning outcomes before and after educational interventions, providing robust evidence of how haematology education contributes to improved understanding and professional development. Key Findings at a Glance 93% of Participants Improved Their Scores With 93% of participants showing measurable improvements, these results demonstrate the clear impact of our educational programmes on HCP performance. 72% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 72% improved 23% remained stable Only 5% saw a decrease The results underline how effective education accommodates diverse learning levels and fosters ongoing growth. 36% Achieved the Top Score After Medical Education Activity Over a third of participants progressed to the top performance group, underscoring the measurable impact of CME on professional learning outcomes. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (41.5%) or Average (39.2%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (45.5%) or Top (36.6%) categories. These findings illustrate that education in medicine is not merely informative; it inspires measurable improvements. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change These gains for HCPs ultimately translate into higher-quality care for patients worldwide. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Insights into oncology learning programmes and their impact on clinical practice and patient care. Oncology is one of the most complex and rapidly advancing areas of medicine, demanding continuous learning from healthcare professionals. But how effective is oncology education in keeping pace with this change? nuaxia analysed extensive behavioural data from oncology-focused educational activities to evaluate how learning interventions support knowledge and competence development. Through sophisticated data science methods, nuaxia measured changes in learning outcomes across oncology education programmes. This analysis provides evidence-based insights into the effectiveness of oncology education, highlighting its role in supporting informed clinical decision-making. Key Findings at a Glance 92% of Participants Improved Their Scores With 92% of participants showing measurable improvements, these results demonstrate the clear impact of our educational programmes on HCP performance. 70% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 70% improved 26% remained stable Only 4% saw a decrease These findings highlight how well-designed CME meets learners where they are and guides them toward higher competence. 33% Achieved the Top Score After Medical Education Activity Importantly, a third of participants progressed to the top performance group, highlighting the role of CME in enabling HCPs to achieve higher levels of performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (45.7%) or High (33.9%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (48.5%) or Top (32.7%) categories. The data confirms that meaningful education in healthcare doesn’t just inform, it shapes practice. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change The impact extends beyond healthcare professionals, enhancing care for patients around the globe. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Exploring evidence-based approaches to immunology education and their effectiveness in knowledge retention. Immunology underpins many of today’s most significant therapeutic advances, from biologics to personalised medicine. As the field evolves, the effectiveness of immunology education becomes increasingly important. nuaxia conducted a detailed analysis of behavioural data from immunology education activities to assess how learning interventions shape professional competence. By examining pre- and post-education performance, nuaxia’s analysis delivers objective insights into how immunology education influences knowledge retention and clinical understanding, offering a clearer view of educational impact in this rapidly advancing discipline. Key Findings at a Glance 93% of Participants Improved Their Scores Nearly all participants achieved improvements in knowledge and competence, underscoring the tangible benefits of our CME initiatives. 69% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 69% improved 29% remained stable Only 2% saw a decrease This shows that structured medical education adapts to HCPs’ starting points while driving measurable development. 41% Achieved the Top Score After Medical Education Activity Notably, 41% of participants reached the top performance group, showing that CME activities are helping a significant portion of HCPs achieve high performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (48.4%) or High (35.6%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (45.8%) or Top (41.4%) categories. This shows that well-designed medical education can transform professional performance, not just understanding. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change Not only do HCPs gain from this education, but patients also experience improved outcomes globally. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com